8 August 2022
Sartorius Acquires Albumedix to Enhance Advanced Therapy Solutions
Sartorius acquires Albumedix for £415M, adding recombinant albumin solutions to its portfolio. This enhances cell culture media and vaccine production capabilities. Transaction closes Q3 2022.
